Results 91 to 100 of about 4,852 (207)

Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?

AIDS reviews, 2016
Tenofovir disoproxil fumarate is currently the cornerstone of HIV treatment. Although it shows an overall good safety profile, numerous cases of nephrotoxicity have been reported. Tenofovir alafenamide is a novel tenofovir prodrug that has been developed to improve renal safety.
Aloy, Blandine, Tazi, Imane, Bagnis, Corinne Isnard, Gauthier, Marion, Janus, Nicolas, Launay-Vacher, Vincent, Deray, Gilbert, Tourret, Jérôme   +7 more
openaire   +2 more sources

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute‐on‐chronic liver failure associated with hepatitis B [PDF]

, 2021
Juan Li, Chunhua Hu, Yi Chen, Rou Zhang, Shan Fu, Mimi Zhou, Zhijie Gao, Mengjun Fu, Taotao Yan, Yuan Yang, ­Jun Li­, Jinfeng Liu, Tianyan Chen, Shihua Zhao, Yingli He   +14 more
openalex   +1 more source

Weight Gain in HIV Adults Receiving Antiretroviral Treatment: Current Knowledge and Future Perspectives

Life
Body weight is impacted by several individual host and environmental factors. In a person living with HIV (PLWH), weight is also influenced by the disease stage.
Konstantinos Markakis, Olga Tsachouridou, Eleni Georgianou, Dimitrios Pilalas, Sideris Nanoudis, Symeon Metallidis   +5 more
doaj   +1 more source

Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B

, 2021
Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park   +9 more
openalex   +2 more sources

Tenofovir alafenamide/tenofovir disoproxil fumarate

Reactions Weekly, 2021
openaire   +1 more source

Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate [PDF]

, 2021
Kensuke Abe, Taku Obara, Satomi Kamio, Asahi Kondo, Junji Imamura, Tatsuya Goto, Toshihiro Ito, Hiroshi Sato, Nobuyuki Takahashi   +8 more
openalex   +1 more source

PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men

, 2020
Gabriel Robles, Daniel Sauermilch, Monica Gandhi, Tyrel J. Starks   +3 more
openalex   +2 more sources

Evaluation of the safety and antiviral efficacy of the tenofovir alafenamide fumarate molecule in immunosuppressed patients

, 2022
Serdar Durak, Arif Coşar
openalex   +2 more sources

Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort

International Journal of Infectious Diseases
Objectives: Long-term effects of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on hepatic, renal, and metabolic parameters remain poorly characterized, especially in people with HIV (PWH) and hepatitis B virus ...
Mariacristina Poliseno, Sergio Lo Caputo, Alessandro Tavelli, Roberta Gagliardini, Lidia Gazzola, Annalisa Saracino, Teresa Antonia Santantonio, Nicola Squillace, Massimo Puoti, Valentina Mazzotta, Adndrea Antinori, Antonella d’Arminio Monforte, Alessandro Cozzi-Lepri   +12 more
doaj   +1 more source